nach oben

Breast Cancer Research and Treatment

Erschienen in:

01.04.2010 | Review

Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more?

verfasst von: Omar S. Din, David Dodwell, Richard J. Wakefield, Robert E. Coleman

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Aromatase inhibitors (AIs) are a standard of care for the adjuvant treatment of hormone responsive early carcinoma of the breast as demonstrated in a number of large international phase III randomised trials. Arthralgia was a somewhat unexpected side effect of this class of agents and has proven to be potentially problematic in clinical practice. Although rates of up 35% have been reported in the randomised trials, the figure has been much higher in subsequent case series. There is concern that these symptoms are significant and may affect compliance and thus the overall efficacy of treatment. It is therefore extremely important that we evaluate this syndrome with a view to gaining more information regarding its clinical features and possible aetiological mechanism. The potential aetiological mechanisms and evidence for aromatase inhibitor-induced arthralgia (AIA) are reviewed in this article. Looking forward, it is now important that prospective clinical trials are well designed to evaluate this syndrome and potential therapeutic strategies to circumvent it. Radiological imaging and biochemical analyses may help our understanding of AIA and these are discussed.

EBCTCG (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717CrossRef

Bonneterre J et al (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18(22):3748–3757PubMed

Mouridsen H et al (2003) Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21(11):2101–2109CrossRefPubMed

Nabholtz JM et al (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18(22):3758–3767PubMed

Howell A et al (2005) Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365(9453):60–62CrossRefPubMed

Goss PE et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349(19):1793–1802CrossRefPubMed

Coombes RC et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350(11):1081–1092CrossRefPubMed

Coombes RC et al (2007) Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369(9561):559–570CrossRefPubMed

Jakesz R et al (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366(9484):455–462CrossRefPubMed

10.

Thurlimann B et al (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353(26):2747–2757CrossRefPubMed

11.

Boccardo F et al (2006) Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 17(7): vii10–4

12.

Yager JD, Davidson NE (2006) Estrogen carcinogenesis in breast cancer. N Engl J Med 354(3):270–282CrossRefPubMed

13.

Njar VC, Brodie AM (1999) Comprehensive pharmacology and clinical efficacy of aromatase inhibitors. Drugs 58(2):233–255CrossRefPubMed

14.

Campos SM (2004) Aromatase inhibitors for breast cancer in postmenopausal women. Oncologist 9(2):126–136CrossRefPubMed

15.

di Salle E et al (1992) Exemestane (FCE 24304), a new steroidal aromatase inhibitor. J Steroid Biochem Mol Biol 43(1–3):137–143PubMed

16.

Greendale GA, Lee NP, Arriola ER (1999) The menopause. Lancet 353(9152):571–580CrossRefPubMed

17.

Cecil RL, Archer BH (1925) Arthritis of the menopause. JAMA 84:75–79

18.

Avis N et al (2004) Baillere’s clinical endocrinology and metabolism. In: Burger H (ed) The evolution of menopausal symptoms. Bailliere Tindall, London

19.

Dugan SA et al (2006) Musculoskeletal pain and menopausal status. Clin J Pain 22(4):325–331CrossRefPubMed

20.

Xu J et al (2005) Natural history of menopause symptoms in primary care patients: a MetroNet study. J Am Board Fam Pract 18(5):374–382CrossRefPubMed

21.

Szoeke CE et al (2008) The relationship of reports of aches and joint pains to the menopausal transition: a longitudinal study. Climacteric 11(1):55–62CrossRefPubMed

22.

Huang C et al (1997) Factors associated with joint pain among postmenopausal women. Int J Obes Relat Metab Disord 21(5):349–354CrossRefPubMed

23.

Dowsett M, Lonning PE (1997) Anastrozole–a new generation in aromatase inhibition: clinical pharmacology. Oncology 54(Suppl 2):11–14CrossRefPubMed

24.

Nielsen RH et al (2008) Oestrogen exhibits type II collagen protective effects and attenuates collagen-induced arthritis in rats. Clin Exp Immunol 152(1):21–27PubMedCrossRef

25.

Cvoro A et al (2008) Selective estrogen receptor-beta agonists repress transcription of proinflammatory genes. J Immunol 180(1):630–636PubMed

26.

Dawson-Basoa M, Gintzler AR (1997) Involvement of spinal cord delta opiate receptors in the antinociception of gestation and its hormonal simulation. Brain Res 757(1):37–42CrossRefPubMed

27.

Riley JL 3rd et al (1999) A meta-analytic review of pain perception across the menstrual cycle. Pain 81(3):225–235CrossRefPubMed

28.

Dietrich W et al (2006) Estrogen receptor-beta is the predominant estrogen receptor subtype in normal human synovia. J Soc Gynecol Investig 13(7):512–517PubMed

29.

Coleman RE et al (2008) Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations. Cancer Treat Rev 34(3):275–282CrossRefPubMed

30.

Richette P, Corvol M, Bardin T (2003) Estrogens, cartilage, and osteoarthritis. Joint Bone Spine 70(4):257–262CrossRefPubMed

31.

Sniekers YH et al (2008) Animal models for osteoarthritis: the effect of ovariectomy and estrogen treatment—a systematic approach. Osteoarthr Cartil 16(5):533–541CrossRefPubMed

32.

Oestergaard S et al (2006) Effects of ovariectomy and estrogen therapy on type II collagen degradation and structural integrity of articular cartilage in rats: implications of the time of initiation. Arthritis Rheum 54(8):2441–2451CrossRefPubMed

33.

Nevitt MC et al (2001) The effect of estrogen plus progestin on knee symptoms and related disability in postmenopausal women: The Heart and Estrogen/Progestin Replacement Study, a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 44(4):811–818CrossRefPubMed

34.

Le Bail J et al (2001) Aromatase in synovial cells from postmenopausal women. Steroids 66(10):749–757CrossRefPubMed

35.

Sasano H et al (1997) Aromatase in human bone tissue. J Bone Miner Res 12(9):1416–1423CrossRefPubMed

36.

Toesca A et al (2008) Estrogen and progesterone receptors in carpal tunnel syndrome. Cell Biol Int 32(1):75–79CrossRefPubMed

37.

Morel B, Marotte H, Miossec P (2007) Will steroidal aromatase inhibitors induce rheumatoid arthritis? Ann Rheum Dis 66(4):557–558CrossRefPubMed

38.

Laroche M et al (2007) Joint pain with aromatase inhibitors: abnormal frequency of Sjogren’s syndrome. J Rheumatol 34(11):2259–2263PubMed

39.

Henry NL et al (2008) Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 111(2):365–372CrossRefPubMed

40.

Pfeilschifter J et al (2002) Changes in proinflammatory cytokine activity after menopause. Endocr Rev 23(1):90–119CrossRefPubMed

41.

Mao JJ et al (2009) Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer 115(16):3631–3639CrossRefPubMed

42.

Sestak I et al (2008) Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol 9(9):866–872CrossRefPubMed

43.

Buzdar A (2006) Clinical features of joint symptoms observed in the ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial. J Clin Oncol 24(18S): 551

44.

Buzdar A et al (2006) Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 7(8):633–643CrossRefPubMed

45.

Fallowfield L et al (2004) Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol 22(21):4261–4271CrossRefPubMed

46.

Cella D et al (2006) Quality of life of postmenopausal women in the ATAC (“Arimidex”, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for early breast cancer. Breast Cancer Res Treat 100(3):273–284CrossRefPubMed

47.

Khanduri S, Dodwell DJ (2007) Aromatase inhibitors and musculoskeletal symptoms. Breast 17(1):76–79CrossRefPubMed

48.

Cuzick J et al (2008) Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 9(12):1143–1148CrossRefPubMed

49.

Fallowfield L (2008) There’s many a slip twixt cup and lip: adherence issues in cancer therapy. Nat Clin Pract Oncol 5(3):118–119CrossRefPubMed

50.

Chlebowski RT, Geller ML (2006) Adherence to endocrine therapy for breast cancer. Oncology 71(1–2):1–9PubMed

51.

Fallowfield LJ et al (2006) Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 24(6):910–917CrossRefPubMed

52.

Whelan TJ et al (2005) Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 23(28):6931–6940CrossRefPubMed

53.

Felson DT (2008) Comparing the prevalence of rheumatic diseases in China with the rest of the world. Arthritis Res Ther 10(1):106CrossRefPubMed

54.

Crew KD et al (2007) Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 25(25):3877–3883CrossRefPubMed

55.

Presant CA et al (2007) Aromatase inhibitor-associated arthralgia and/or bone pain: frequency and characterization in non-clinical trial patients. Clin Breast Cancer 7(10):775–778CrossRefPubMed

56.

Dent SF et al (2007) Adjuvant aromatse inhibitors in early breast cancer—toxicity and adherence. Important observations in clinical practice. In: San Antonio breast cancer symposium. San Antonio, Texas

57.

Renshaw L et al (2007) Comparison of joint problems as reported by patients in a randomised adjuvant trial of anastrozole and letrozole. In: San Antonio breast caner symposium, p 2072

58.

Morales L et al (2007) Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. Breast Cancer Res Treat 104(1):87–91CrossRefPubMed

59.

Morales L et al (2008) Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol 26(19):3147–3152CrossRefPubMed

60.

Alegre-Sancho JJ et al (2008) Trigger thumb in patients with breast cancer and hand pain associated with aromatase inhibitors. Ann Rheum Dis 67(Suppl II)

61.

Dizdar O et al (2009) Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor-related arthralgia. J Clin Oncol 27(30):4955–4960CrossRefPubMed

62.

Sestak I, Sapunar F, Cuzick J (2009) Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial. J Clin Oncol 27(30):4961–4965CrossRefPubMed

63.

Sestak I, Cuzick J (2007) Risk factors for joint symptoms in the ATAC trial. In: San Antonio breast caner symposium, p 2071

64.

Singh S, Howell A, Cuzick J (2006) Vit D levels among patients with arthralgia: results from IBIS-II breast cancer prevention study. In: San Antonio breast caner symposium, p 1068

65.

Azria D et al (2007) Letrozole induced arthralgia: results of a multicentric prospective trial exploring clinical parameters and plasma biomarkers. In: ASCO breast cancer symposium, p 228

66.

Khan QJ et al (2010) Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat 119(1):111–118CrossRefPubMed

67.

Mao JJ et al (2009) Feasibility trial of electroacupuncture for aromatase inhibitor-related arthralgia in breast cancer survivors. Integr Cancer Ther 8(2):123–129CrossRefPubMed

68.

Crew KD et al (2009) Randomized, blinded, placebo-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer. J Clin Oncol 27(15s): 571

69.

Basch E et al (2006) Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol 7(11):903–909CrossRefPubMed

70.

Hershman DL (2008) Getting a grip on aromatase inhibitor-associated arthralgias. J Clin Oncol 26(19):3120–3121CrossRefPubMed

71.

Allen KD et al (2007) Validity and factor structure of the AUSCAN Osteoarthritis Hand Index in a community-based sample. Osteoarthr Cartil 15(7):830–836CrossRefPubMed

72.

Sautner J et al (2004) Development of the M-SACRAH, a modified, shortened version of SACRAH (Score for the Assessment and Quantification of Chronic Rheumatoid Affections of the Hands). Rheumatology 43(11):1409–1413CrossRefPubMed

73.

Sautner J et al (2009) A comparison of the Modified Score for the Assessment of Chronic Rheumatoid Affections of the Hands and the Australian/Canadian Osteoarthritis Hand Index in Hand Osteoarthritis Patients. Int J Rheumatol 1–7

74.

Harkonen R, Harju R, Alaranta H (1993) Accuracy of the Jamar dynamometer. J Hand Ther 6(4):259–262PubMed

75.

Mathiowetz V et al (1984) Reliability and validity of grip and pinch strength evaluations. J Hand Surg Am 9(2):222–226PubMed

76.

Backhaus M et al (2001) Guidelines for musculoskeletal ultrasound in rheumatology. Ann Rheum Dis 60(7):641–649CrossRefPubMed

77.

Wakefield RJ et al (2005) Musculoskeletal ultrasound including definitions for ultrasonographic pathology. J Rheumatol 32(12):2485–2487PubMed

78.

Schmidt WA (2007) Technology insight: the role of color and power Doppler ultrasonography in rheumatology. Nat Clin Pract Rheumatol. 3(1): 35–42 (quiz 59)

79.

Tan AL, Emery P (2008) Role of oestrogen in the development of joint symptoms? Lancet Oncol 9(9):817–818CrossRefPubMed

80.

Tan AL et al (2003) Imaging of the musculoskeletal system: magnetic resonance imaging, ultrasonography and computed tomography. Best Pract Res Clin Rheumatol 17(3):513–528CrossRefPubMed

81.

Haavardsholm EA et al (2007) Introduction of a novel magnetic resonance imaging tenosynovitis score for rheumatoid arthritis: reliability in a multireader longitudinal study. Ann Rheum Dis 66(9):1216–1220CrossRefPubMed

82.

Haavardsholm EA et al (2005) Reliability and sensitivity to change of the OMERACT rheumatoid arthritis magnetic resonance imaging score in a multireader, longitudinal setting. Arthritis Rheum 52(12):3860–3867CrossRefPubMed

83.

Lester JE et al (2008) Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 14(19):6336–6342CrossRefPubMed

84.

Brufsky A et al (2008) Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 13(5):503–514CrossRefPubMed

85.

Ellis GK et al (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26(30):4875–4882CrossRefPubMed

86.

Haugeberg G et al (2006) Hand bone loss in early undifferentiated arthritis: evaluating bone mineral density loss before the development of rheumatoid arthritis. Ann Rheum Dis 65(6):736–740CrossRefPubMed

87.

Haugeberg G et al (2007) Hand bone densitometry: a more sensitive standard for the assessment of early bone damage in rheumatoid arthritis. Ann Rheum Dis 66(11):1513–1517CrossRefPubMed

88.

Henry NL et al (2008) A distinct inflammatory marker pattern in patients with aromatase inhibitor (AI)-induced musculoskeletal symptoms. In: SABCS. San Antonio, Texas

89.

Hunter DJ et al (2007) Cartilage markers and their association with cartilage loss on magnetic resonance imaging in knee osteoarthritis: the Boston Osteoarthritis Knee Study. Arthritis Res Ther 9(5):R108CrossRefPubMed

90.

Williams FM, Spector TD (2008) Biomarkers in osteoarthritis. Arthritis Res Ther 10(1):101CrossRefPubMed

91.

Landewe R (2007) Predictive markers in rapidly progressing rheumatoid arthritis. J Rheumatol Suppl 80:8–15PubMed

92.

Wild N et al (2008) Diagnosis of rheumatoid arthritis: multivariate analysis of biomarkers. Biomarkers 13(1):88–105CrossRefPubMed

93.

ClinicalTrials.gov. 2009 7th July 2009]; Available from: http://clinicaltrials.gov/ct2/results?term=breast+cancer+AND+arthralgia

94.

Jakesz R et al (2007) Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst 99(24):1845–1853CrossRefPubMed

95.

Burstein HJ (2007) Aromatase inhibitor-associated arthralgia syndrome. Breast 16(3):223–234CrossRefPubMed

96.

Bianchi S et al. (2007) Ultrasound of the digital flexor system: normal and pathological findings. J Ultrasound 10:85–92CrossRef

Titel: Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more?
verfasst von: Omar S. Din
David Dodwell
Richard J. Wakefield
Robert E. Coleman
Publikationsdatum: 01.04.2010
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 3/2010
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-010-0757-7

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more?

Abstract

Neu im Fachgebiet Onkologie

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Antikörper mobilisiert Neutrophile gegen Krebs

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2010

Psychological distress and physical health in the year after diagnosis of DCIS or invasive breast cancer

Silica-gold nanoshells as potential intraoperative molecular probes for HER2-overexpression in ex vivo breast tissue using near-infrared reflectance confocal microscopy

Three common TP53 polymorphisms in susceptibility to breast cancer, evidence from meta-analysis

Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women

The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer

CpG island methylation affects accessibility of the proximal BRCA1 promoter to transcription factors

Neu im Fachgebiet Onkologie

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Antikörper mobilisiert Neutrophile gegen Krebs

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Update Onkologie